The colony-forming assays showed this combination harbored significantly better anti-tumor activity than the single drug, indicating the LRPPRC-mediated OXPHOS could also promote CDK4/6i resistance in LUAD (Fig. 5b, c). The gene discussed is CDK4; the disease is neoplasm.